Vivos Inc. announced that it has completed its planned dosing schedule to determine the effectiveness of using the company’s proprietary RadioGel™ therapy to treat feline sarcoma. An initial study of two cats was completed in September 2017 at Washington State University (WSU). The results of that study indicated RadioGel performed as designed, confirming objective response (destruction of tumor tissue) without any negative or detrimental side-effects. Subsequently, an additional three cats with advanced cases of sarcoma were treated, two in December 2017 and one in January 2018. As planned, the additional treatment program was completed at higher radiation doses to optimize levels for therapy. Dosimetry calculations show that lethal doses to the cancer cells will occur over the first ten days, after which, less than 5% of the radiation will remain in the animals. It will take approximately three months for the biopsy and follow-up analysis to further confirm the effectiveness of the therapy. The final report from these studies will be shared with VCA as part of the company's continuing discussions about a business relationship in private veterinarian clinics. The next step will be to generate data on the treatment of canine sarcoma at the University of Missouri. These data will also be shared with the private clinic consortiums and with the FDA as part of the company's pre-clinical testing for the use of RadioGel in humans.